Alector (ALEC) closed at $2.09 on November 5, 2026, down 8.3% from the previous close, on volume of 1,206,368 shares (30-day average 5,239,445).
Data as of November 5, 2026.
Alector’s AL137 Pipeline and Financial Runway Support Buy Rating; $6 Price Target Maintained
TipRanks (Fri, 6-Nov 9:31 AM ET)
TipRanks (Fri, 6-Nov 7:50 AM ET)
Alector GAAP EPS of $1.11 beats by $1.10
Seeking Alpha News (Thu, 5-Nov 5:55 PM ET)
Alector Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Thu, 5-Nov 4:05 PM ET)
Alector Announces Pricing of Underwritten Offering
Globe Newswire (Fri, 16-Oct 7:30 AM ET)
Globe Newswire (Wed, 7-Oct 4:05 PM ET)
Market Chameleon (Mon, 5-Oct 5:54 AM ET)
Biotech Brainiacs and Breakthroughs
Globe Newswire (Mon, 5-Oct 9:51 AM ET)
Market Chameleon (Mon, 5-Oct 4:13 AM ET)
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
Alector trades on the NASDAQ stock market under the symbol ALEC.
As of November 6, 2026, ALEC stock price climbed to $2.18 with 129,498 million shares trading.
ALEC has a beta of 2.12, meaning it tends to be more sensitive to market movements. ALEC has a correlation of 0.10 to the broad based SPY ETF.
ALEC has a market cap of $243.41 million. This is considered a Small Cap stock.
Last quarter Alector reported $163 million in Revenue and $1.11 earnings per share. This beat revenue expectation by $139 million and exceeded earnings estimates by $1.33.
In the last 3 years, ALEC traded as high as $8.90 and as low as $.87.
The top ETF exchange traded funds that ALEC belongs to (by Net Assets): IWM, VTI, VXF, IWO, SCHA.
ALEC has outperformed the market in the last year with a price return of +73.7% while the SPY ETF gained +10.3%. ALEC has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +46.3% and +19.1%, respectively, while the SPY returned -3.6% and -3.1%, respectively.
ALEC support price is $1.96 and resistance is $2.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALEC shares will trade within this expected range on the day.
